VSIG4 and COVID-19: VSIG4 also inhibits activation of a nonclassical complement pathway by binding to C3b59,60, leading additional credence to the idea that the particular pathway of complement activation is one of the factors determining survival outcomes in COVID-19 patients, since its overexpression is linked to survival in our data.